<DOC>
	<DOCNO>NCT00546650</DOCNO>
	<brief_summary>The primary objective compare pharmacokinetics ( PK ) NP101 currently approve oral , injection nasal spray formulation Imitrex® healthy volunteer assess bioavailability relative 6 mg subcutaneous injection . The secondary objective evaluate safety NP101 healthy volunteer .</brief_summary>
	<brief_title>Phase I Study Compare NP101 ( Sumatriptan Iontophoretic Transdermal Patch ) With Three Formulations Imitrex®</brief_title>
	<detailed_description />
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Healthy men woman age 18 65 year . Women childbearing potential must use medically acceptable form birth control duration study , must negative serum pregnancy test screen negative urine pregnancy test Day 1 period . Subjects must body mass index ( BMI ) 18 30 kg/m2 inclusive . Subjects must able communicate effectively study personnel . Subjects must , investigator 's opinion , clinically significant disease abnormal laboratory value determine medical psychiatric history , physical examination , laboratory evaluation conduct screen visit clinic admission . Subjects must 12lead ECG without clinically significant abnormality rate , rhythm , interval conduction , determine investigator . Subjects must nonsmoker , define use tobacco product 6 month screen . Subjects must consume alcoholic beverage , poppy seed , grapefruit , and/or grapefruit juice within 72 hour prior admission clinic Period 1 duration study . Subjects must adequately inform nature risk study give write informed consent prior screen . The subject must likely complete entire study . Female subject pregnant breast feed plan pregnancy study . A known hypersensitivity sumatriptan triptan agent recipient formulation . Subject currently hypertension blood pressure outside normal range age group . Subject hemiplegic basilar migraine . Subject severe hepatic impairment . Subject skin irritation disease might interfere absorption study drug skin irritation assessment , include eczema , psoriasis , melanoma , acne . Subject tattoo might interfere skin erythema examination . Subject positive test result hepatitis B , C know HIV positive medical history AIDS . Subject administer injectable drug , except local anesthetic birth control , within 30 day prior initial study drug administration . Subject require medication regular basis . Subject history malignancy within past 5 year ( except squamous basal cell carcinoma skin treat evidence recurrence ) . Subject hemoglobin ( Hgb ) level le 7.5 mmol/L . Subject history , symptom , sign ischemic cardiac , cerebrovascular , peripheral vascular syndrome . Recent ( within one year screening ) history alcohol abuse , illicit drug use , physical dependence opioid , recent ( within one year screening ) history drug abuse addiction . Concurrent use prescription ( Rx ) overthecounter ( OTC ) medication natural medicine ( herbal ) product . Subject currently take MAOA inhibitor Receipt investigational drug participation clinical study within 90 day prior study entry . Donation blood blood product within 8 week prior study entry . Positive urine drug screen , include ethanol , cocaine , THC , barbiturates , amphetamine , benzodiazepine , opiate . Subject consider investigator NuPathe , reason , unsuitable candidate receiving sumatriptan , unsuitable reason judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Focus study compare pharmacokinetics</keyword>
</DOC>